JPH0449229A - Composition for cutis - Google Patents
Composition for cutisInfo
- Publication number
- JPH0449229A JPH0449229A JP2160665A JP16066590A JPH0449229A JP H0449229 A JPH0449229 A JP H0449229A JP 2160665 A JP2160665 A JP 2160665A JP 16066590 A JP16066590 A JP 16066590A JP H0449229 A JPH0449229 A JP H0449229A
- Authority
- JP
- Japan
- Prior art keywords
- fibers
- cutis
- skin
- liquid drug
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 239000000835 fiber Substances 0.000 claims abstract description 35
- 239000007788 liquid Substances 0.000 claims abstract description 24
- 229920000728 polyester Polymers 0.000 claims abstract description 24
- 239000000126 substance Substances 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000000417 fungicide Substances 0.000 claims description 6
- 239000002657 fibrous material Substances 0.000 claims description 5
- 230000000855 fungicidal effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 15
- 239000004745 nonwoven fabric Substances 0.000 abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 14
- 229960000686 benzalkonium chloride Drugs 0.000 abstract description 12
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract description 12
- -1 cataplasm Substances 0.000 abstract description 9
- 229920000742 Cotton Polymers 0.000 abstract description 8
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 5
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 3
- 230000001139 anti-pruritic effect Effects 0.000 abstract description 3
- 239000003908 antipruritic agent Substances 0.000 abstract description 3
- 239000003212 astringent agent Substances 0.000 abstract description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 abstract description 2
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 239000003213 antiperspirant Substances 0.000 abstract description 2
- 229960003260 chlorhexidine Drugs 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 239000002075 main ingredient Substances 0.000 abstract description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 abstract 1
- 239000002390 adhesive tape Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 20
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 15
- 229910052782 aluminium Inorganic materials 0.000 description 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 7
- 229960000458 allantoin Drugs 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 7
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 7
- 239000003899 bactericide agent Substances 0.000 description 6
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 5
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 5
- 229960004760 naphazoline hydrochloride Drugs 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229920000297 Rayon Polymers 0.000 description 4
- 239000002964 rayon Substances 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 229920003043 Cellulose fiber Polymers 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- PVYDNJADTSAQQU-UHFFFAOYSA-N prop-1-ene;hydrochloride Chemical group Cl.CC=C PVYDNJADTSAQQU-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000005470 impregnation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 235000014692 zinc oxide Nutrition 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- XHPZWIWFOBUOHK-UHFFFAOYSA-N 7,8,9,11-tetrahydro-6h-pyrido[2,1-b]quinazoline;hydrochloride Chemical compound Cl.C1=CC=C2CN(CCCC3)C3=NC2=C1 XHPZWIWFOBUOHK-UHFFFAOYSA-N 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 229920002978 Vinylon Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 229960001378 dequalinium chloride Drugs 0.000 description 1
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- VTKMMWSAJLCWSM-UHFFFAOYSA-H dialuminum;5-(carbamoylamino)-2-oxo-1,5-dihydroimidazol-4-olate;chloride;tetrahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-].NC(=O)NC1NC(=O)N=C1[O-] VTKMMWSAJLCWSM-UHFFFAOYSA-H 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229960003072 epinephrine hydrochloride Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960003517 isothipendyl Drugs 0.000 description 1
- OQJBSDFFQWMKBQ-UHFFFAOYSA-N isothipendyl Chemical compound C1=CN=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 OQJBSDFFQWMKBQ-UHFFFAOYSA-N 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940051020 methylephedrine hydrochloride Drugs 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 208000022196 parasitic skin disease Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
【発明の詳細な説明】 [産業上の利用分野] 本発明は、外皮用組成物に関する。[Detailed description of the invention] [Industrial application field] The present invention relates to dermal compositions.
さらに詳しくは、担体として、ポリエステル繊維、また
はポリエステル繊維と他の繊維との混合物からなる不織
布を選び、これに殺菌剤を含む外皮用液剤を吸収させた
外皮用組成物に関する。More specifically, the present invention relates to a skin composition in which a nonwoven fabric made of polyester fibers or a mixture of polyester fibers and other fibers is selected as a carrier, and a skin liquid containing a fungicide is absorbed therein.
[従来の技術]
従来クロルヘキシジン、塩化ベンザルコニウム等の外皮
用殺菌剤溶液を脱脂綿、ガーゼ等のセルロース繊維に吸
収させたものが、皮膚の殺菌消毒に用いられてきた。[Prior Art] Conventionally, a solution of a skin disinfectant such as chlorhexidine or benzalkonium chloride absorbed into cellulose fibers such as absorbent cotton or gauze has been used to disinfect and disinfect the skin.
しかし、これらの殺菌消毒組成物は、薬剤のほとんとか
セルロース繊維に吸着し、薬剤の効果が著しく低下する
ことが知られていた。However, it has been known that most of the drugs in these sterilizing and disinfecting compositions are adsorbed to cellulose fibers, significantly reducing the effectiveness of the drugs.
かかる解決方法として、特開昭50−18616号公報
、および特開昭50−18617号公報に示されるよう
に、2価以上の金属塩あるいは高級アルコール硫酸エス
テル塩を添加する方法があった。As a method for solving this problem, there has been a method of adding a divalent or higher valent metal salt or a higher alcohol sulfate ester salt, as shown in JP-A-50-18616 and JP-A-50-18617.
しかしながら、これらの方法はいずれも完全に満足し得
るものではなく、例えば2価以上の金属塩の添加におい
ては、吸着防止効果の良い塩化カルシウムは局所刺激が
強く、また塩化マグネシウムは苦味が非常に強いため、
例えば乳首の清拭には使用できないという欠点を有した
。However, none of these methods are completely satisfactory; for example, when adding divalent or higher valent metal salts, calcium chloride, which has a good adsorption prevention effect, causes strong local irritation, and magnesium chloride has a very bitter taste. Because it is strong,
For example, it had the disadvantage that it could not be used to clean nipples.
一方、高級アルコール硫酸エステル塩の添加においては
、外皮用殺菌剤の殺菌力が減退するという問題があり、
また、高級アルコール硫酸エステル塩自体も皮膚に対し
て好ましくない作用(浸透性、刺激性)を有する。On the other hand, when adding higher alcohol sulfate ester salts, there is a problem in that the bactericidal activity of the skin fungicide decreases.
Further, higher alcohol sulfate salts themselves have unfavorable effects on the skin (penetration, irritation).
更に、これらの吸着防止法として、特開昭621986
9号公報に記載されたような、1価の金属塩(例えば塩
化ナトリウム)を添加する方法があリ、これによりセル
ロース、綿からのクロルヘキシジングルコネート等の外
皮用殺菌剤の吸着をある程度防止できるが、完全な形で
吸着防止はできない。Furthermore, as a method for preventing these adsorptions, Japanese Patent Application Laid-Open No. 621986
There is a method of adding a monovalent metal salt (for example, sodium chloride) as described in Publication No. 9, which can prevent to some extent the adsorption of skin fungicides such as chlorhexidine gluconate from cellulose and cotton. However, it is not possible to completely prevent adsorption.
[発明が解決しようとする課題]
上記のような添加剤を配合せず、しかも、良好に薬剤を
溶出させることについて、永年に亘り検討した結果、坦
体として化学繊維、特にポリエステル繊維を用いた場合
に殺菌剤を含む外皮用液剤がほとんど吸着されず、有効
成分の効果を十分に発揮できることを見い出し、発明を
完成した。[Problem to be solved by the invention] As a result of many years of study on how to elute drugs well without adding the above additives, we have developed a method using chemical fibers, especially polyester fibers, as carriers. The inventors completed the invention by discovering that in some cases, a liquid preparation for the skin containing a bactericide is hardly adsorbed, and the effect of the active ingredient can be fully exerted.
[構成]
本発明の外皮組成物は殺菌剤を含む外皮用液剤を吸収さ
せた、ポリエステル繊維を含む化学繊維素材よりなる。[Structure] The skin composition of the present invention is made of a chemical fiber material containing polyester fibers, which has been absorbed with a liquid agent for skin containing a fungicide.
上記、「ポリエステル繊維を含む、化学繊維素材」とは
、殺菌剤を含む外皮用液剤をほとんど吸着しないポリエ
ステル繊維が、繊維の表面を、十分な程度に覆っている
化学繊維素材であり、例えば、
(1)ポリエステル繊維のみからなる素材、(2)熱融
着繊維の如く、他の化学繊維を繊維芯材として用い、さ
や成分としてポリエステルを使用した素材、
(3)ポリエステル繊維とを他の化学繊維とを混綿した
素材
等を挙げることができ、従って、ポリエステル繊維と他
の化学繊維とをそれぞれ0〜100%の比率で混合する
ことができる。The above-mentioned "chemical fiber material containing polyester fibers" is a chemical fiber material in which the surface of the fibers is sufficiently covered with polyester fibers that hardly absorb liquid agents for outer skin containing disinfectants. (1) Materials consisting only of polyester fibers, (2) Materials that use other chemical fibers as the fiber core material and polyester as the sheath component, such as heat-fused fibers, (3) Materials that use polyester fibers and other chemical fibers as the sheath component. Examples include materials in which polyester fibers are mixed with other chemical fibers, and therefore, polyester fibers and other chemical fibers can be mixed at a ratio of 0 to 100%, respectively.
ここで、「他の化学繊維」とは、ポリエチレン、レーヨ
ン、ナイロン、ポリプロピレン、ビニロン、ポリアミド
のような化学繊維を挙げることができる。Here, "other chemical fibers" include chemical fibers such as polyethylene, rayon, nylon, polypropylene, vinylon, and polyamide.
なお、化学繊維素材は不織布であることが好ましく、更
にかかる不織布は皮膚への触感がよく、耐薬品性があり
、液体の吸蔵能が大きく、かつ内容成分が吸着されない
特性を有することが好ましい。The chemical fiber material is preferably a non-woven fabric, and it is further preferable that such a non-woven fabric feels good on the skin, has chemical resistance, has a large liquid storage capacity, and has the characteristics that the contents are not adsorbed.
例えばポリエステル不織布では、目付40〜44mg/
II+2、厚さ0.46a+fflの不織布は1g当た
り6〜8fflLの液体で吸蔵させることが好適である
。For example, polyester nonwoven fabric has a basis weight of 40 to 44 mg/
It is suitable that the nonwoven fabric having a thickness of II+2 and a thickness of 0.46a+ffl is occluded with 6 to 8 ffl/g of liquid.
前記「殺菌剤を含む外皮用液剤」とは、主剤として、殺
菌剤を含む外皮用液剤をいい、かかる「殺菌剤」として
は、例えば塩化ベンザルコニウム、塩化ベンゼトニウム
、塩酸クロルヘキシジン、クロルヘキシジングルコネー
ト、ポビドンヨード、アクリノール、塩化デカリニウム
、セトノミドのようなイオン性の殺菌剤を挙げることが
できる。The above-mentioned "liquid for skin containing a bactericide" refers to a liquid for skin that contains a bactericide as a main ingredient, and such "bactericide" includes, for example, benzalkonium chloride, benzethonium chloride, chlorhexidine hydrochloride, chlorhexidine gluconate, Mention may be made of ionic fungicides such as povidone-iodine, acrinol, dequalinium chloride, cetonomide.
なお、「殺菌剤を含む外皮用液剤」は外皮用薬剤におい
て、一般に使用される他の薬剤を含んでいても良く、か
かる薬剤としては、アミノ安息香酸エチル、ジブカイン
(またはその塩酸塩)、プロ力イン(またはその塩酸塩
)、リドカイン(またはその塩酸塩)、グリチルリチン
酸(またはその塩)、クリチルレチン酸、インドメタシ
ン、副腎皮質ステロイド剤のような局所麻酔、鎮痛・消
炎剤、塩酸テトラゾリン、塩酸ナファゾリン、塩酸フェ
ニレフリン、dff−塩酸メチルエフェドリン、塩酸エ
ピネフリンのような血管収縮剤、マレイン酸クロルフェ
ニラミン、ジフェンヒドラミン(またはその塩)、塩酸
イソチペンジルのような抗ヒスタミン剤、酸化亜鉛、カ
ラミン、硫酸アルミニウムカリウム、アラントイン、ア
ルミニクムクロルヒドロキシアラントイネート等のアラ
ントインの誘導体のような収斂剤、クロタミトン、メン
トール、カンフル、サリチル酸メチルのような鎮痒剤、
およびビタミン類、また、安息香酸およびそのナトリウ
ム塩、パラオキシ安息香酸メチル、パラオキシ安息香酸
エチル、パラオキシ安息香酸プロピル、バラオキシ安息
香酸イソプロピル、バラオキシ安息香酸ブチル、バラオ
キシ安息香酸イソブチル、ソルビン酸およびそのカリウ
ム塩、デヒドロ酢酸およびそのナトリウム塩、プロピオ
ン酸カルシウム、プロピオン酸ナトリウムのような防腐
剤を挙げることができる。The "liquid for skin containing a bactericide" may also contain other drugs commonly used for skin, such as ethyl aminobenzoate, dibucaine (or its hydrochloride), probiotics, etc. Local anesthetics, analgesics and anti-inflammatories such as Licoin (or its hydrochloride), lidocaine (or its hydrochloride), glycyrrhizic acid (or its salts), clycyrrhetinic acid, indomethacin, corticosteroids, tetrazoline hydrochloride, naphazoline hydrochloride , phenylephrine hydrochloride, dff-methylephedrine hydrochloride, vasoconstrictors such as epinephrine hydrochloride, chlorpheniramine maleate, diphenhydramine (or its salts), antihistamines such as isothipendyl hydrochloride, zinc oxide, calamine, potassium aluminum sulfate, allantoin, astringents such as derivatives of allantoin such as aluminum chlorhydroxyallantoinate, antipruritics such as crotamiton, menthol, camphor, methyl salicylate;
and vitamins, as well as benzoic acid and its sodium salt, methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, isopropyl paraoxybenzoate, butyl paraoxybenzoate, isobutyl paraoxybenzoate, sorbic acid and its potassium salt, Mention may be made of preservatives such as dehydroacetic acid and its sodium salt, calcium propionate, sodium propionate.
また、「殺菌剤を含む外皮用液剤」に配合される薬剤の
濃度は、一般に医薬品、医薬部外品および化粧品に汎用
されている配合量で良い。Furthermore, the concentration of the drug added to the "liquid for skin containing a bactericide" may be the amount commonly used in pharmaceuticals, quasi-drugs, and cosmetics.
外皮用液剤の溶媒としては、上記を溶解し、かつ皮膚刺
激の少ないものが使用でき、例えば水、含水エタノール
、マクロゴール、グルセリン、プロピレングリコールの
ような水性溶媒、ミグリオール、トウモロコシ油、ラッ
カセイ油、オリーブ油、ナタネ油、ゴマ油、流動パラフ
ィンのような油性溶媒を挙げることができる。As the solvent for the liquid preparation for the skin, those that dissolve the above and are less irritating to the skin can be used, such as water, aqueous solvents such as hydrated ethanol, macrogol, glycerin, and propylene glycol, miglyol, corn oil, peanut oil, Mention may be made of oily solvents such as olive oil, rapeseed oil, sesame oil, liquid paraffin.
[効果]
以下の試験例に示すように、本発明の組成物たるポリエ
ステル単独あるいは、ポリエステル繊維とレーヨンから
なる繊維は、従来のセルロース繊維のみからなる綿に比
べて、吸着はほとんど認められず、皮膚への触感が優れ
る。[Effects] As shown in the test examples below, the composition of the present invention, which is polyester alone or fibers made of polyester fibers and rayon, exhibits almost no adsorption compared to conventional cotton made only of cellulose fibers. Excellent feel to the skin.
[試験例] 試験例における残存率は次の方法にて求めた。[Test example] The survival rate in the test example was determined by the following method.
l)塩化ベンザルコニウム
含浸液および絞り液各々311に内標準液(塩酸ジフェ
ンヒドラミン0.1%液)を加え、精製水で正確に10
+nlとし、各々30μmについて液体クロマトグラフ
法により試験を行い、内標準物質のピーク面積に対する
塩化ベンザルコニウムのピーク面積比Qt(絞り液)お
よびQs(含浸液)を求め算出した。l) Add an internal standard solution (diphenhydramine hydrochloride 0.1% solution) to 311 ml of each of the benzalkonium chloride impregnating solution and squeezing solution, and dilute to exactly 10 ml with purified water.
+nl, and a test was conducted by liquid chromatography for each 30 μm, and the peak area ratios Qt (squeezing solution) and Qs (impregnating solution) of benzalkonium chloride to the peak area of the internal standard substance were determined and calculated.
残存率(%)−〇t
Qs X100
2)塩酸ナファゾリン、塩酸ジブヵイン含浸液および絞
り液111に内標準液(塩酸プロ力イン0.1%溶液)
1mlを加え、精製水で正確に25a+1とし、各々2
0μmについて液体クロマトグラフ法により試験を行い
、内標準物質のピーク面積に対する各薬剤のビークコ積
比qt(絞り液)および(ls(含浸液)′を求め、次
式により残存率を算出した。Residual rate (%) -〇t Qs
Add 1ml, make exactly 25a+1 with purified water, and make 25a+1 each.
A test was conducted using liquid chromatography at 0 μm, and the beak volume ratios qt (squeezing solution) and (ls (impregnating solution)) of each drug to the peak area of the internal standard were determined, and the residual rate was calculated using the following formula.
残存率(%)−〇t
Qsxloo
3)クロルヘキシジングルコネート
含浸液および絞り液の各々200L11を水で希釈して
20m1とした。Residual rate (%) -〇t Qsxloo 3) 200L11 of each of the chlorhexidine gluconate impregnating liquid and squeezing liquid was diluted with water to make 20ml.
水を対照として、波長197nfflにおける吸光度E
t (絞り液)およびEs (標準液)を測定し、残存
率を算出した。Absorbance E at wavelength 197nffl with water as a control
t (squeezed liquid) and Es (standard solution) were measured, and the residual rate was calculated.
4)塩酸プロ力イン
含浸液および絞り液の各々に内標準液(塩酸プロ力イン
0,1%溶液)3mlを加え、移動相で20m1とした
。試料溶液および標準溶液20μmにつき液体クロマト
グラフ法で試験を行い、内標準物質のピーク面積に対す
る塩酸プロ力インのピーク面積の比Qt(絞り液)およ
びQs (含浸液)を求め、残存率を算出した。4) 3 ml of an internal standard solution (0.1% solution of hydrochloric acid propylene) was added to each of the hydrochloric acid propylene impregnating solution and the squeezing solution, and the total volume was made up to 20 ml with the mobile phase. Test the sample solution and standard solution with a liquid chromatography method of 20 μm, determine the ratio of the peak area of pro-hydrochloric acid to the peak area of the internal standard substance, Qt (squeezing solution) and Qs (impregnating solution), and calculate the residual rate. did.
5)アラントイン 局外規のアラントイン定量法を適用。5) Allantoin The allantoin quantitative method prescribed by the local government was applied.
[試験例1]
塩化ベンザルコニウムの0.1%溶液を調製し、その1
mlを種々の化学繊維からなる不織布0.15gに含浸
させ、アルミラミネート袋に密封し、室温で72時間ま
で放置したときの絞り液中の塩化ベンザルコニウムの残
存率の経時変化をみた。[Test Example 1] Prepare a 0.1% solution of benzalkonium chloride, Part 1
ml was impregnated into 0.15 g of nonwoven fabric made of various chemical fibers, sealed in an aluminum laminate bag, and left at room temperature for up to 72 hours. Changes in the residual rate of benzalkonium chloride in the squeezing solution over time were observed.
表1から明らかなように、種々の化学繊維からなる不織
布からの塩化ベンザルコニウムの各時間における残存率
の変化をみると、4時間で吸着が平衡状態となり、化学
繊維からなる不織布は、局方脱脂綿に比較し、明らかに
残存率の差がみられた。As is clear from Table 1, looking at the changes in the residual rate of benzalkonium chloride from nonwoven fabrics made of various chemical fibers over time, the adsorption reached an equilibrium state in 4 hours, and the nonwoven fabric made of chemical fibers There was a clear difference in the residual rate compared to cotton wool.
[試験例2]
各実施例等の組成物の、含浸4時間後の絞り液表2に示
すように、各薬剤の残存率を本発明外皮用組成物と対照
を比較すると、本発明の組成物は吸着率が著しく低く、
よって効果は優れていることが明らかである。[Test Example 2] Squeezed liquid after 4 hours of impregnation of the compositions of each example, etc. As shown in Table 2, when the residual rate of each drug was compared between the skin composition of the present invention and the control, it was found that the composition of the present invention The adsorption rate of substances is extremely low;
Therefore, it is clear that the effect is excellent.
し試験例3]
各実施例等の組成物の含浸4時間後の絞り液を表3に示
すように、各薬剤の残存率を本発明外皮用組成物と、対
照を比較すると、本発明の組成物は、吸着率が著しく低
く、よって効果は優れていることが明らかである。[Test Example 3] As shown in Table 3, the squeezed liquid after 4 hours of impregnation with the compositions of each example, etc., shows that when the residual rate of each drug is compared with the skin composition of the present invention and the control, it is found that It is clear that the composition has a significantly lower adsorption rate and therefore its effectiveness is excellent.
以上のように本願発明の外皮用組成物は、従来の組成物
と比較し、繊維への吸着が殆どなく、外皮用として有用
な組成物である。As described above, the composition for outer skin of the present invention has almost no adsorption to fibers than conventional compositions, and is a useful composition for outer skin.
従って本発明の組成物は、殺菌消毒綿、おてふき、創傷
保護剤(救急絆創膏、殺菌ガーゼ)、鎮痛・鎮痒・収斂
・消炎剤(かゆみ止め等)、パップ剤、寄生性皮膚疾患
剤(みすむし薬)、褥瘉治療剤、痔疾用剤、制汗・消臭
剤、化膿性疾患用剤および経皮吸収剤として用いること
ができる。Therefore, the composition of the present invention can be used as sterilizing cotton, towelettes, wound protectants (emergency bandages, sterile gauze), analgesic, antipruritic, astringent, and antiinflammatory agents (anti-itching agents, etc.), poultices, parasitic skin disease agents ( It can be used as a decubitus ulcer treatment agent, a hemorrhoid agent, an antiperspirant/deodorant, an agent for purulent diseases, and a transdermal absorption agent.
[製造例]
次に製造例等をあげて、本発明を更に具体的に説明する
が、本発明はこれによって限定されるものではない。[Production Examples] Next, the present invention will be explained in more detail with reference to Production Examples, but the present invention is not limited thereto.
対照例1
塩化ベンザルコニウムo、 Ig、塩酸ナファゾリン0
.1g、塩酸ジブカイン0.1gを蒸留水に溶解し、全
量を100m1とした。この液1+nlを局方脱脂綿’
0.15gに含浸させた後、アルミラミネート袋に密封
した。Control example 1 Benzalkonium chloride o, Ig, naphazoline hydrochloride 0
.. 1 g of dibucaine hydrochloride and 0.1 g of dibucaine hydrochloride were dissolved in distilled water to make a total volume of 100 ml. Dispense 1+nl of this solution onto a pharmacologically absorbent cotton pad.
After impregnating 0.15 g, it was sealed in an aluminum laminate bag.
実施例1
塩化ベンザルコニウム0.1g、塩酸ナファゾリン0、
1g、塩酸ジブカインQ、 Igを蒸留水に溶解し、全
量を100m+1とした。この液1+nlをポリエステ
ル100%からなる不織布0.15gに含浸させた後、
アルミラミネート袋に密封した。Example 1 Benzalkonium chloride 0.1 g, naphazoline hydrochloride 0,
1 g of dibucaine hydrochloride Q and Ig were dissolved in distilled water, and the total amount was adjusted to 100 m+1. After impregnating 0.15 g of a nonwoven fabric made of 100% polyester with 1+nl of this liquid,
Sealed in an aluminum laminated bag.
実施例2
塩化ベンザルコニウム0.1g、塩酸ナファゾリン0.
1g、塩酸ジブカインO,Igを蒸留水に溶解し、全量
を100m1とした。この液1mlをポリエステル70
%およびレーヨン30%からなる不織布0.15gに含
浸させた後、アルミラミネート袋に密封した。Example 2 0.1 g of benzalkonium chloride, 0.1 g of naphazoline hydrochloride.
1 g of dibucaine hydrochloride O, Ig was dissolved in distilled water, and the total volume was adjusted to 100 ml. Add 1 ml of this solution to polyester 70
After impregnating 0.15 g of a nonwoven fabric consisting of 30% and 30% rayon, it was sealed in an aluminum laminate bag.
実施例3
塩化ベンザルコニウム0.1g、塩酸ナファゾリン0.
1巳、塩酸ジブカイン0.1gを蒸留水に溶解し、全量
を100 ff1lとした。この液1+nlをポリエス
テル50%およびポリエチレン50%からなる不織布0
.15gに含浸させた後、アルミラミネート袋に密封し
た。Example 3 0.1 g of benzalkonium chloride, 0.1 g of naphazoline hydrochloride.
0.1 g of dibucaine hydrochloride was dissolved in distilled water, and the total amount was adjusted to 100 ffl. 1+nl of this solution was applied to a nonwoven fabric made of 50% polyester and 50% polyethylene.
.. After impregnating 15 g, it was sealed in an aluminum laminate bag.
対照例2
クロルヘキシジングルコネート0.1g、塩酸プロ力イ
ン1g、アラントイン0.1gを蒸留水に溶解し、全量
を100 mlとした。この液1a+1を局方脱脂綿0
.15gに含浸させた後、アルミラミネート袋に密封し
た。Control Example 2 0.1 g of chlorhexidine gluconate, 1 g of prolactin hydrochloride, and 0.1 g of allantoin were dissolved in distilled water to make a total volume of 100 ml. Add this solution 1a+1 to 0% cotton
.. After impregnating 15 g, it was sealed in an aluminum laminate bag.
実施例4
クロルヘキシジングルコネート0.1g、塩酸プロ力イ
ン1g、アラントイン0.1gを蒸留水に溶解し、全量
を100 mlとした。この液1a+1をポリエステル
100%からなる不織布0.15gに含浸させた後、ア
ルミラミネート袋に密封した。Example 4 0.1 g of chlorhexidine gluconate, 1 g of propyroin hydrochloride, and 0.1 g of allantoin were dissolved in distilled water to make a total volume of 100 ml. After impregnating 0.15 g of a nonwoven fabric made of 100% polyester with this liquid 1a+1, it was sealed in an aluminum laminate bag.
実施例5
クロルヘキシジングルコネート0.1g、塩酸プロ力イ
ン1g、アラントインO,Igを蒸留水に溶解し、全量
を100 mlとした。この液Lo11をポリエステル
70%およびレーヨン30%からなる不織布0.15g
に含浸させた後、アルミラミネート袋に密封した。Example 5 0.1 g of chlorhexidine gluconate, 1 g of propylene hydrochloride, and allantoin O and Ig were dissolved in distilled water to make a total volume of 100 ml. 0.15g of this liquid Lo11 was added to a nonwoven fabric made of 70% polyester and 30% rayon.
After impregnating it with water, it was sealed in an aluminum laminated bag.
実施例6
クロルヘキシジングルコネートO,1g、塩酸プロ力イ
ン1g、アラントイン0.1[を蒸留水に溶解し、全量
を100 mlとした。この液1mlをポリエステル5
0%およびポリエチレン50%がらな5不織布0.15
gに含浸させた後、アルミラミネート袋に密封した。Example 6 1 g of chlorhexidine gluconate O, 1 g of propyroin hydrochloride, and 0.1 g of allantoin were dissolved in distilled water to make a total volume of 100 ml. Add 1 ml of this solution to polyester 5
0% and 50% polyethylene non-woven fabric 0.15
After impregnating it with g, it was sealed in an aluminum laminate bag.
出願人 和光堂株式会社 代理人 弁理士 大 野 彰 夫Applicant: Wakodo Co., Ltd. Agent: Patent Attorney Akio Ohno
Claims (1)
外皮用液剤を吸収させることよりなる外皮用組成物。A composition for skins made by absorbing a liquid agent for skins containing a fungicide into a chemical fiber material containing polyester fibers.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2160665A JPH0741062B2 (en) | 1990-06-19 | 1990-06-19 | Composition for outer skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2160665A JPH0741062B2 (en) | 1990-06-19 | 1990-06-19 | Composition for outer skin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0449229A true JPH0449229A (en) | 1992-02-18 |
JPH0741062B2 JPH0741062B2 (en) | 1995-05-10 |
Family
ID=15719845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2160665A Expired - Fee Related JPH0741062B2 (en) | 1990-06-19 | 1990-06-19 | Composition for outer skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0741062B2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2701397A1 (en) * | 1993-02-12 | 1994-08-19 | Lemaire Henry | Product for topical administration of medicinal or cosmetic substances |
US5591052A (en) * | 1994-06-23 | 1997-01-07 | Yazaki Corporation | Connector with a double locking mechanism |
US7427574B2 (en) * | 2005-08-19 | 2008-09-23 | Sage Products, Inc. | Non-woven wash cloth |
JP2009256338A (en) * | 2008-03-24 | 2009-11-05 | Asahi Kasei Chemicals Corp | Sterilizing disinfectant-containing wet wiper |
US7823727B2 (en) | 2005-06-29 | 2010-11-02 | Sage Products, Inc. | Patient check system |
JP2012514641A (en) * | 2009-01-06 | 2012-06-28 | ベクトン・ディキンソン・アンド・カンパニー | Chlorhexidine acetate disinfectant cleaner |
JP2019097756A (en) * | 2017-11-30 | 2019-06-24 | 株式会社ニイタカ | Wet wiper |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102495182A (en) * | 2011-12-15 | 2012-06-13 | 上海景峰制药有限公司 | Novel quantitative germicidal test carrier for disinfectant |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6411556A (en) * | 1987-07-03 | 1989-01-17 | Teisan Seiyaku Kk | Injury protecting agent |
-
1990
- 1990-06-19 JP JP2160665A patent/JPH0741062B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6411556A (en) * | 1987-07-03 | 1989-01-17 | Teisan Seiyaku Kk | Injury protecting agent |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2701397A1 (en) * | 1993-02-12 | 1994-08-19 | Lemaire Henry | Product for topical administration of medicinal or cosmetic substances |
US5591052A (en) * | 1994-06-23 | 1997-01-07 | Yazaki Corporation | Connector with a double locking mechanism |
US7823727B2 (en) | 2005-06-29 | 2010-11-02 | Sage Products, Inc. | Patient check system |
US7427574B2 (en) * | 2005-08-19 | 2008-09-23 | Sage Products, Inc. | Non-woven wash cloth |
JP2009256338A (en) * | 2008-03-24 | 2009-11-05 | Asahi Kasei Chemicals Corp | Sterilizing disinfectant-containing wet wiper |
JP2012514641A (en) * | 2009-01-06 | 2012-06-28 | ベクトン・ディキンソン・アンド・カンパニー | Chlorhexidine acetate disinfectant cleaner |
JP2019097756A (en) * | 2017-11-30 | 2019-06-24 | 株式会社ニイタカ | Wet wiper |
Also Published As
Publication number | Publication date |
---|---|
JPH0741062B2 (en) | 1995-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014203072B2 (en) | Topical glycopyrrolate formulations | |
KR101393853B1 (en) | Transdermal delivery of oleocanthal for relief of inflammation | |
US3624224A (en) | Novel first aid products | |
US5665378A (en) | Transdermal therapeutic formulation | |
JP5693470B2 (en) | Disinfectant composition containing silver ions and menthol and use thereof | |
WO2001047559A9 (en) | Patches for external use | |
CA1238275A (en) | Menthol enhancement of transdermal drug delivery | |
JP6554474B2 (en) | Traumatic wound dressing system including wrap | |
JPH0449229A (en) | Composition for cutis | |
JP2000191521A (en) | Sterilizer | |
JP2002212105A (en) | Aqueous skin care composition | |
JP2004210668A (en) | Medicine composition for external use | |
US20120061267A1 (en) | MediTowel Anti-Fungal Wipe | |
JPH08109137A (en) | Capsule, thin sheet for storing medicine, bag-like formulation and production thereof and method for administrating bag-like formulation | |
EP0918521B1 (en) | Formulation for the treatment and/or prophylaxis of dementia | |
JP2002145762A (en) | Wet tissue-type liniment, packaged wet tissue-type liniment and method for applying | |
WO2003026710A1 (en) | Mixture for use as a protective dressing | |
JP2003040703A (en) | Noxious insect-repelling agent for human body | |
RU2171694C1 (en) | Medical product | |
JP2540861B2 (en) | Poultice | |
JPH01313062A (en) | External remedy for cold | |
RU35717U1 (en) | Disposable sanitizer (options) | |
AU721101C (en) | Formulation for the treatment and/or prophylaxis of dementia | |
IL34659A (en) | An antiseptic composition comprising a germicidal quaternary ammonium compound,a poly(oxyethylene)-poly(oxypropylene)-block polymer and a local anaesthetic | |
Wang et al. | Over-the-Counter Medications: Toxic Effects and Adverse Reactions: Part I |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080510 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090510 Year of fee payment: 14 |
|
LAPS | Cancellation because of no payment of annual fees |